Compare GLBS & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLBS | RNTX |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | Greece | United States |
| Employees | N/A | 10 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 47.7M |
| IPO Year | 2010 | N/A |
| Metric | GLBS | RNTX |
|---|---|---|
| Price | $2.15 | $1.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $10.00 |
| AVG Volume (30 Days) | 59.2K | ★ 841.5K |
| Earning Date | 06-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.06 | N/A |
| Revenue Next Year | $20.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.95 |
| 52 Week High | $2.44 | $2.18 |
| Indicator | GLBS | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.00 | 39.26 |
| Support Level | $1.83 | N/A |
| Resistance Level | $2.18 | $1.33 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 75.00 | 24.94 |
Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.